483 related articles for article (PubMed ID: 23737488)
1. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
2. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
[TBL] [Abstract][Full Text] [Related]
3. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
4. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
[TBL] [Abstract][Full Text] [Related]
5. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
[TBL] [Abstract][Full Text] [Related]
6. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury.
Bönner F; Borg N; Burghoff S; Schrader J
PLoS One; 2012; 7(4):e34730. PubMed ID: 22514659
[TBL] [Abstract][Full Text] [Related]
7. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
8. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
[TBL] [Abstract][Full Text] [Related]
9. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
11. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
13. Adenosinergic Immunosuppression by Human Mesenchymal Stromal Cells Requires Co-Operation with T cells.
Kerkelä E; Laitinen A; Räbinä J; Valkonen S; Takatalo M; Larjo A; Veijola J; Lampinen M; Siljander P; Lehenkari P; Alfthan K; Laitinen S
Stem Cells; 2016 Mar; 34(3):781-90. PubMed ID: 26731338
[TBL] [Abstract][Full Text] [Related]
14. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
15. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
16. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
17. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
18. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
[TBL] [Abstract][Full Text] [Related]
19. Altered CD39 and CD73 Expression in Rheumatoid Arthritis: Implications for Disease Activity and Treatment Response.
Ortiz MA; Diaz-Torné C; De Agustin JJ; Estrada P; Reina D; Hernandez MV; Sang H; Zamora C; Cantó E; Corominas H; Vidal S
Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38275742
[TBL] [Abstract][Full Text] [Related]
20. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
